Clinical Trials Sponsored by Gemstone Biotherapeutics

Total 383 results

Gemstone Biotherapeutics

Unknown

Briagen Observational Study (BOS)

Mohs Surgery

United States
Keystone Heart

Completed

The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

Symptomatic Aortic Stenosis

United States, Netherlands, Germany, Italy
Keystone Heart

Completed

A Study to Evaluate the Neuro-embolic Consequences of TAVR

Aortic Valve Stenosis

United States
Keystone Heart

Completed

DEFLECT I: Keystone Heart Embolic Deflection Trial

Aortic Stenosis
Keystone Heart

Completed

DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI (TAVI)

Aortic Valve Stenosis

Netherlands, Israel, United Kingdom, Germany, France, Italy
Keystone Heart

Completed

DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR

Aortic Valve Stenosis

Netherlands
Medstone International

Terminated

Lithotripsy for the Treatment of Gallstones

Cholelithiasis

United States
Barinthus Biotherapeutics

Not yet recruiting

VTP-1000 in Adults With Celiac Disease

Celiac Disease
Fore Biotherapeutics

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations

United States, Germany, Spain, United Kingdom, Korea, Republic of, Italy, France, Sweden, Canada
Sonnet BioTherapeutics

Recruiting

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Tavotek Biotherapeutics

Active, not recruiting

Study of TAVO101 in Healthy Volunteers

Healthy Subjects

Australia
Tavotek Biotherapeutics

Completed

Study of TAVO103A in Healthy Volunteers

Healthy Subjects

United States
Revolo Biotherapeutics

Completed

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Revolo Biotherapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Healthy Volunteer

United States
Sonnet BioTherapeutics

Completed

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Healthy Adult

Australia
Aeglea Biotherapeutics

Terminated

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Homocystinuria Due to Cystathionine Beta-Synthase Deficiency

United States, United Kingdom, Australia
Atara Biotherapeutics

No longer available

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Fore Biotherapeutics

Completed

NovellusDx Tissue Collection Protocol

Patients That Have Been Diagnosed With Colorectal Cancer | Patients Eligible for Tumor Biopsy

Israel
Eleven Biotherapeutics

Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Diabetic Macular Edema
Eleven Biotherapeutics

Unknown

Study of EBI-005 in Dry Eye Disease (DED) (EBI-005)

Dry Eye

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Alethia Biotherapeutics

Recruiting

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003)

Metastatic Colorectal Cancer

Canada
Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
Barinthus Biotherapeutics

Completed

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

HPV Infection | CIN1

Belgium, United Kingdom, Estonia
BrightPath Biotherapeutics

Terminated

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Metastatic NSCLC

United States
Northwest Biotherapeutics

Active, not recruiting

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)

Glioma | Glioblastoma | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States, Germany, Canada, United Kingdom
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Advanced Cancers

United States
Alethia Biotherapeutics

Completed

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

Solid Tumor | Metastatic Cancer

Canada
Eleven Biotherapeutics

Completed

Phase 3 Study of EBI-005 in Dry Eye Disease (EBI-005)

Dry Eye Disease (DED)

United States
Eleven Biotherapeutics

Completed

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Allergic Conjunctivitis

Canada
Eleven Biotherapeutics

Completed

A Multi-Center Study Subjects With Dry Eye Syndrome (EBI)

Dry Eye Syndrome

United States
Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
Northwest Biotherapeutics

Withdrawn

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Prostate Cancer

United States
Jennerex Biotherapeutics

Terminated

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Colorectal Carcinoma

Canada
Tavotek Biotherapeutics

Recruiting

A Study of TAVO412 in Patients With Cancer (TAVO412)

Cancer

United States
Excision BioTherapeutics

Recruiting

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

HIV-1-infection

United States
Sonnet BioTherapeutics

Terminated

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Australia
Fore Biotherapeutics

Active, not recruiting

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Advanced Unresectable Solid Tumors | BRAF-mutated Tumors

United States
Alethia Biotherapeutics

Completed

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

NSCLC Stage IV

United States, Canada
Atara Biotherapeutics

Terminated

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (EMBOLD)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States, Australia, Canada
Excision BioTherapeutics

Enrolling by invitation

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

HIV-1-infection

United States
Aeglea Biotherapeutics

Terminated

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

Canada
Aeglea Biotherapeutics

Completed

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102)

Arginase I Deficiency | Hyperargininemia

United States, Canada, United Kingdom, Portugal
Aeglea Biotherapeutics

Completed

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

United States, Italy, Canada, France, United Kingdom, Austria, Germany
Revolo Biotherapeutics

Completed

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United Kingdom
Revolo Biotherapeutics

Completed

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Healthy Volunteer

United Kingdom

Clinical Trials Sponsored by Gemstone Biotherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations